129 related articles for article (PubMed ID: 7752587)
1. Impaired metabolic response to recombinant insulin-like growth factor-1 in dialysis patients.
Fouque D; Peng SC; Kopple JD
Kidney Int; 1995 Mar; 47(3):876-83. PubMed ID: 7752587
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of recombinant human insulin-like growth factor-1 in dialysis patients.
Fouque D; Peng SC; Kopple JD
Kidney Int; 1995 Mar; 47(3):869-75. PubMed ID: 7752586
[TBL] [Abstract][Full Text] [Related]
3. Low dose recombinant human insulin-like growth factor-I fails to affect protein anabolism but inhibits islet cell secretion in humans.
Mauras N; Horber FF; Haymond MW
J Clin Endocrinol Metab; 1992 Nov; 75(5):1192-7. PubMed ID: 1430078
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients.
Fouque D; Peng SC; Shamir E; Kopple JD
Kidney Int; 2000 Feb; 57(2):646-54. PubMed ID: 10652043
[TBL] [Abstract][Full Text] [Related]
5. The effect of recombinant human IGF-I on protein metabolism in post-operative patients without nutrition compared to effects in experimental animals.
Sandström R; Svanberg E; Hyltander A; Haglind E; Ohlsson C; Zachrisson H; Berglund B; Lindholm E; Brevinge H; Lundholm K
Eur J Clin Invest; 1995 Oct; 25(10):784-92. PubMed ID: 8557066
[TBL] [Abstract][Full Text] [Related]
6. Effect of insulin-like growth factor-1 on the responses to and recognition of hypoglycemia in humans. A comparison with insulin.
Kerr D; Tamborlane WV; Rife F; Sherwin RS
J Clin Invest; 1993 Jan; 91(1):141-7. PubMed ID: 8423214
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults.
Boulware SD; Tamborlane WV; Rennert NJ; Gesundheit N; Sherwin RS
J Clin Invest; 1994 Mar; 93(3):1131-9. PubMed ID: 8132753
[TBL] [Abstract][Full Text] [Related]
8. The effect of recombinant IGF-I on anterior pituitary function in healthy volunteers.
Trainer PJ; Holly J; Medbak S; Rees LH; Besser GM
Clin Endocrinol (Oxf); 1994 Dec; 41(6):801-7. PubMed ID: 7889617
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human insulin-like growth factor I, recombinant human growth hormone, and sex steroids: effects on markers of bone turnover in humans.
Mauras N; Doi SQ; Shapiro JR
J Clin Endocrinol Metab; 1996 Jun; 81(6):2222-6. PubMed ID: 8964855
[TBL] [Abstract][Full Text] [Related]
10. rhIGF-I administration in humans: differential metabolic effects of bolus vs. continuous subcutaneous delivery.
Mauras N; Martha PM; Quarmby V; Haymond MW
Am J Physiol; 1997 Apr; 272(4 Pt 1):E628-33. PubMed ID: 9142884
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
Saukkonen T; Amin R; Williams RM; Fox C; Yuen KC; White MA; Umpleby AM; Acerini CL; Dunger DB
J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
[TBL] [Abstract][Full Text] [Related]
12. Short-term administration of a combination of recombinant growth hormone and insulin-like growth factor-I induces anabolism in maintenance hemodialysis.
Guebre-Egziabher F; Juillard L; Boirie Y; Laville M; Beaufrère B; Fouque D
J Clin Endocrinol Metab; 2009 Jul; 94(7):2299-305. PubMed ID: 19401377
[TBL] [Abstract][Full Text] [Related]
13. Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion.
Zenobi PD; Graf S; Ursprung H; Froesch ER
J Clin Invest; 1992 Jun; 89(6):1908-13. PubMed ID: 1601998
[TBL] [Abstract][Full Text] [Related]
14. Metabolic effects of rhIGF-1 in normal human subjects.
Rennert NJ; Boulware SD; Kerr D; Caprio S; Tamborlane WV; Sherwin RS
Adv Exp Med Biol; 1993; 343():311-8. PubMed ID: 8184741
[No Abstract] [Full Text] [Related]
15. Response of young broiler chickens to chronic injection of recombinant-derived human insulin-like growth factor-I.
McGuinness MC; Cogburn LA
Domest Anim Endocrinol; 1991 Oct; 8(4):611-20. PubMed ID: 1786708
[TBL] [Abstract][Full Text] [Related]
16. Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus.
Acerini CL; Harris DA; Matyka KA; Watts AP; Umpleby AM; Russell-Jones DL; Dunger DB
Metabolism; 1998 Dec; 47(12):1481-9. PubMed ID: 9867078
[TBL] [Abstract][Full Text] [Related]
17. Short- and long-term metabolic effects of recombinant human IGF-I treatment in patients with severe insulin resistance and diabetes mellitus.
Vestergaard H; Rossen M; Urhammer SA; Müller J; Pedersen O
Eur J Endocrinol; 1997 May; 136(5):475-82. PubMed ID: 9186267
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect.
Mauras N; Beaufrere B
J Clin Endocrinol Metab; 1995 Mar; 80(3):869-74. PubMed ID: 7533772
[TBL] [Abstract][Full Text] [Related]
19. Altered physiology and action of insulin-like growth factor 1 in skeletal muscle in chronic renal failure.
Kopple JD; Ding H; Gao XL
Am J Kidney Dis; 1995 Jul; 26(1):248-55. PubMed ID: 7611259
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human insulin-like growth factor (IGF)-binding protein-1 inhibits somatic growth stimulated by IGF-I and growth hormone in hypophysectomized rats.
Cox GN; McDermott MJ; Merkel E; Stroh CA; Ko SC; Squires CH; Gleason TM; Russell D
Endocrinology; 1994 Nov; 135(5):1913-20. PubMed ID: 7525258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
